WO2017152539A1 - 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 - Google Patents
一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 Download PDFInfo
- Publication number
- WO2017152539A1 WO2017152539A1 PCT/CN2016/086772 CN2016086772W WO2017152539A1 WO 2017152539 A1 WO2017152539 A1 WO 2017152539A1 CN 2016086772 W CN2016086772 W CN 2016086772W WO 2017152539 A1 WO2017152539 A1 WO 2017152539A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hours
- group
- reaction
- acid
- Prior art date
Links
- 0 CCOC(C1=Cc(cc(cc2*)S(F)(F)(F)(F)F)c2OC1C(F)(F)F)=O Chemical compound CCOC(C1=Cc(cc(cc2*)S(F)(F)(F)(F)F)c2OC1C(F)(F)F)=O 0.000 description 9
- WMHRLCGQEILUCD-UHFFFAOYSA-N CC1C=CC=NC1C Chemical compound CC1C=CC=NC1C WMHRLCGQEILUCD-UHFFFAOYSA-N 0.000 description 1
- QTSNWWOIHVKQHY-UHFFFAOYSA-N CN(C1)CN2CN1CN(C)C2 Chemical compound CN(C1)CN2CN1CN(C)C2 QTSNWWOIHVKQHY-UHFFFAOYSA-N 0.000 description 1
- BHLZAJPXLXRFAO-UHFFFAOYSA-N Nc(cc1C=O)ccc1O Chemical compound Nc(cc1C=O)ccc1O BHLZAJPXLXRFAO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- Inflammation is a common and frequently-occurring disease that endangers human health and affects the quality of human life.
- the most common form of arthritis there are currently about 355 million arthritis patients worldwide.
- the number of arthritis patients in China is estimated to be about 100 million and is increasing every year. Therefore, the development of anti-inflammatory and analgesic drugs is of great significance.
- COX Cyclooxygenase
- COX-1 is present in normal tissues, catalyzing the synthesis of PGE2 and PGI2, and has cell stabilization and cytoprotection.
- COX-2 is cytokine-inducible, and it is only present in damaged tissues. The prostaglandin synthesized by COX-2 is inflammatory and has an inflammatory and pain-causing effect.
- Sulfur pentafluoride-substituted benzopyrans are differentiated from bisarylcycloheximide compounds and have the same pharmacodynamics and selectivity as bisarylcycloheximide compounds, ie, selective
- the inhibition of the action of COX-2 enzyme, its structural formula is as follows
- the solvent is used in an amount of 10 to 20 mL, for example, 10 mL, 11 mL, 12 mL, 13 mL, 14 mL, 15 mL, 16 mL, 17 mL, 18 mL, 19 mL or 20 mL, relative to 1 g of the compound I.
- R 1 is selected from the group consisting of hydrogen, a C 1 -C 10 alkyl group, a C 6 -C 15 alkylaryl group or a C 3 -C 8 heterocyclic group, and R 2 is a halogen.
- R 1 is selected from any one of a C 1 -C 8 alkyl group, a C 6 -C 11 alkylaryl group or a C 4 -C 6 heterocyclic group;
- R 1 is selected from the group consisting of hydrogen, a C 1 -C 10 alkyl group, a C 6 -C 15 alkylaryl group or a C 3 -C 8 heterocyclic group, and R 2 is a halogen.
- the temperature of the reaction is from 60 to 100 ° C, such as 60 ° C, 65 ° C, 70 ° C, 75 ° C, 80 ° C, 85 ° C, 90 ° C, 95 ° C or 100 ° C.
- the 4-pentafluorosulfur phenol compound represented by the formulae II and III (b) is two intermediates for preparing a sulfur pentafluoride-substituted benzopyran compound.
- the reaction of the compound II with the chloroformate in the step (1) is carried out in the presence of a weakly basic substance; preferably, the weakly basic substance is triethylamine, potassium carbonate, cesium carbonate or cesium fluoride. Any one or a combination of at least two is preferably triethylamine.
- the molar ratio of the compound II to the weakly basic substance is 1:2 to 10, for example, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10, preferably 1:6.
- the temperature of the reaction of the compound II with the chloroformate in the step (1) is 0 to 30 ° C, for example, 0 ° C, 3 ° C, 5 ° C, 8 ° C, 10 ° C, 13 ° C, 15 ° C, 18 ° C, 20 ° C, 22 ° C, 25 ° C, 28 ° C or 30 ° C.
- the temperature of the reaction of the compound II in the step (1) with sodium borohydride is 0-30 ° C, such as 0 ° C, 3 ° C, 5 ° C, 8 ° C, 10 ° C, 13 ° C, 15 ° C, 18 ° C, 20 °C, 22°C, 25°C, 28°C or 30°C.
- the reaction time of the compound II in the step (1) with sodium borohydride is 1-5 hours, for example, 1 hour, 1.3 hours, 1.5 hours, 1.8 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 Hours, 4.5 hours or 5 hours.
- the acid solution of step (2) is any one of trifluoroacetic acid, polyphosphoric acid or glacial acetic acid or a combination of at least two, preferably trifluoroacetic acid.
- the molar ratio of the compound III (a) to the hexamethylenetetramine in the step (2) is 1:1.2 to 2, for example, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1: 1.6, 1:1.7, 1:1.8, 1:1.9 or 1:2, preferably 1:1.7.
- the temperature of the reaction in the step (2) is 60 to 100 ° C, for example, 60 ° C, 63 ° C, 65 ° C, 68 ° C, 70 ° C, 73 ° C, 75 ° C, 78 ° C, 80 ° C, 82 ° C, 85 °C, 88 ° C, 90 ° C, 92 ° C, 95 ° C, 98 ° C or 100 ° C, preferably 80 ° C.
- the reaction time in the step (2) is 8-48 hours, for example, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours. Hours, 33 hours, 36 hours, 38 hours, 40 hours, 44 hours or 48 hours, preferably 12-18 hours.
- the weak base in the step (3) is any one of a triethylamine, potassium carbonate, cesium carbonate or cesium fluoride or a combination of at least two, preferably triethylamine.
- the temperature of the reaction in the step (3) is 80-120 ° C, for example, 80 ° C, 83 ° C, 85 ° C, 88 ° C, 90 ° C, 93 ° C, 95 ° C, 98 ° C, 100 ° C, 103 ° C, 105 °C, 108 ° C, 110 ° C, 112 ° C, 115 ° C, 118 ° C or 120 ° C.
- the reaction time in the step (3) is 10 to 72 hours, for example, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 28 hours, 30 hours, 36 Hour, 40 hours, 44 hours, 48 hours, 52 hours, 56 hours, 60 hours, 65 hours, 68 hours or 72 hours, preferably 12-20 hours.
- the base in the step (4) is any one of potassium hydroxide, sodium hydroxide or lithium hydroxide or a combination of at least two.
- the molar ratio of the compound V to the base in the step (4) is 1:10-20, such as 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1: 16, 1:17, 1:18, 1:19 or 1:20.
- the temperature of hydrolysis with alkali in step (4) is 20-30 ° C, such as 20 ° C, 21 ° C, 22 ° C, 23 ° C, 24 ° C, 25 ° C, 26 ° C, 27 ° C, 28 ° C, 29 ° C Or 30 ° C.
- the hydrolysis with alkali described in step (4) is from 1 to 5 hours, such as 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours or 5 hours.
- the acid of step (4) is hydrochloric acid and/or sulfuric acid.
- R 1 and R are independently selected from the group consisting of hydrogen, a C 1 -C 10 alkyl group, a C 6 -C 15 alkylaryl group or a C 3 -C 8 heterocyclic group.
- the product VI prepared by the preparation method is a racemic compound, and in order to obtain a chiral compound, a chiral catalyst can be added to the reaction of the compound IV with ethyl 4,4,4-trifluorocrotonate.
- the chiral catalyst is a diphenylammonium silicate or a dinaphthyl sulfonium compound; further preferably, the chiral catalyst is (2S)-2-[diphenyl[( Trimethylsilyl)oxy]methyl]-pyrrolidine or (2R)-2-[diphenyl[(trimethylsilyl)oxy]methyl]-pyrrolidine.
- the molar ratio of the chiral catalyst to the compound IV is 1:4-6, such as 1:4.2, 1:4.4, 1:4.6, 1:4.8, 1:5, 1:5.2, 1:5.5, 1:5.8 or 1:6, preferably 1:5.
- the present invention provides a process for the preparation of another sulfur pentafluoride-substituted benzopyran compound, which is prepared by the intermediate compound III (b) to obtain a product IV (b), which comprises the preparation method comprising The following steps:
- R 1 is selected from the group consisting of hydrogen, a C 1 -C 10 alkyl group, a C 6 -C 15 alkylaryl group or a C 3 -C 8 heterocyclic group, and R 2 is a halogen.
- the reaction time in step A is 5-24 hours, such as 5 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours or 24 hours.
- the molar ratio of compound IV (b) to ethyl 4,4,4-trifluorocrotonate in step B is 1:1.2 to 10, for example, 1:1.2, 1:1.5, 1:1.8, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1: 6. 1:7, 1:8, 1:9 or 1:10, preferably 1:5.
- the weak base in step B is any one or a combination of at least two of triethylamine, potassium carbonate, cesium carbonate or cesium fluoride, preferably triethylamine.
- the amount of weak base used in step B is 10-20 mL, for example 10 mL, 11 mL, 12 mL, 13 mL, 14 mL, 15 mL, 16 mL, 18 mL, 19 mL or 20 mL, relative to 1 g of compound IV (b).
- the solvent in step B is any one of triethylamine, tetrahydrofuran, N,N-dimethylformamide or dimethyl sulfoxide or a combination of at least two.
- the temperature of the reaction in step B is 80-120 ° C, such as 80 ° C, 83 ° C, 85 ° C, 88 ° C, 90 ° C, 93 ° C, 95 ° C, 98 ° C, 100 ° C, 103 ° C, 105 ° C, 108 ° C, 110 ° C, 112 ° C, 115 ° C, 118 ° C or 120 ° C.
- the reaction time in the step B is 10 to 72 hours, for example, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 28 hours, 30 hours, 36 hours, 40 hours, 44 hours, 48 hours, 52 hours, 56 hours, 60 hours, 65 hours, 68 hours or 72 hours, preferably 12-20 hours.
- the temperature of hydrolysis with alkali in step C is 20-30 ° C, such as 20 ° C, 21 ° C, 22 ° C, 23 ° C, 24 ° C, 25 ° C, 26 ° C, 27 ° C, 28 ° C, 29 ° C or 30 °C.
- the time of hydrolysis with alkali in step C is 1-5 hours, for example 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours or 5 hours.
- the acid in step C is hydrochloric acid and/or sulfuric acid.
- the method for preparing a sulfur pentafluoride-substituted benzopyran compound according to the sixth aspect of the present invention specifically comprises the following steps:
- R 1 is selected from the group consisting of hydrogen, a C 1 -C 10 alkyl group, a C 6 -C 15 alkylaryl group or a C 3 -C 8 heterocyclic group, and R 2 is a halogen.
- R 1 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, phenyl, benzyl and substituted benzyl Base or Any one of them, R 2 is selected from the group consisting of F, Br, Cl or I.
- the product VI prepared by the preparation method is also a racemic compound, and in order to obtain a chiral compound, the compound IV(b) and 4,4,4-trifluoro can be used.
- Croton A chiral catalyst is added to the reaction of the ethyl ester.
- the chiral catalyst is a diphenylammonium silicate or a dinaphthyl sulfonium compound; further preferably, the chiral catalyst is (2S)-2-[diphenyl[( Trimethylsilyl)oxy]methyl]-pyrrolidine or (2R)-2-[diphenyl[(trimethylsilyl)oxy]methyl]-pyrrolidine.
- the molar ratio of the chiral catalyst to the compound IV (b) is 1:4-6, such as 1:4.2, 1:4.4, 1:4.6, 1:4.8, 1:5, 1:5.2, 1 : 5.5, 1:5.8 or 1:6, preferably 1:5.
- the C 1 - C 10 (for example, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 ,
- the C 8 , C 9 or C 10 )alkyl group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, neopentyl, n-hexyl , n-heptyl, n-octyl, n-decyl, n-decyl, etc., preferably C 1 -C 5 alkyl;
- the C 6 -C 15 alkylaryl means an alkane having 6 to 15 carbon atoms
- the aryl group may, for example, be a C 6 , C 7 , C 8 , C 9 , C 10 , C 11
- the present invention has the following beneficial effects:
- a plurality of sulfur pentafluoride-substituted benzopyran compounds can be synthesized, which overcomes the current low type of sulfur pentafluoride phenol and cannot satisfy the synthesis of various sulfur pentafluoride-substituted benzopyrans.
- the disadvantages of the demand, and the present invention can synthesize a plurality of substituted pentafluoride phenol phenol intermediates under mild conditions using a relatively inexpensive raw material, thereby synthesizing a sulfur pentafluoride-substituted benzopyran compound.
- the synthetic route is as follows:
- the crude product (theoretical value 0.40 g, 1.61 mmol) obtained in step 2 was cooled in ice-cooling, triethylamine (9.6 mmol, 1.05 g), and chloroformic acid The ester (0.52 g, 4.80 mmol) was stirred for 30 min.
- the solvent was distilled off under reduced pressure to give a solid residue (3 mL), which was slowly added dropwise to a sodium borohydride (1.5 g, 38.4 mmol) aqueous solution (5 mL), and stirred for 0.5 hour. Stir to room temperature for 1.5 hours.
- step 3 4-pentafluoride-2-methyl-phenol (0.30 g, 1.3 mmol) was dissolved in trifluoroacetic acid (6 mL), and then hexamethylene was slowly added to the solution.
- the tetraamine (0.31 g, 2.22 mmol) was reacted at a temperature of 80 ° C for 12 h, the heating was stopped and cooled to room temperature, and 3 mL of hydrochloric acid (3 mol/L) was added thereto, followed by stirring for 0.5 h. After completion of the reaction, the mixture was extracted with EtOAc. EtOAc (EtOAc)
- the synthetic route is as follows:
- the synthesis method of this embodiment differs from Example 2 only in that the format reagent used in the step (2) is ethylmagnesium bromide, and the molar ratio thereof to 5-pentafluorosulfide-2-hydroxybenzaldehyde is 4:1, except that the preparation methods and conditions were the same as in Example 2, and characterized by nuclear magnetic resonance spectroscopy and mass spectrometry to determine 6-pentafluoride-8-propyl-2-trifluoromethyl-2H-
- the structure of benzopyran-3-carboxylic acid is as follows:
- the synthesis method of this embodiment differs from Example 2 only in that the format reagent used in the step (2) is propyl magnesium bromide, and the molar ratio thereof to 5-pentafluorosulfide-2-hydroxybenzaldehyde is 4:1, except for the preparation methods and conditions are the same as in Example 2, characterized by nuclear magnetic resonance and mass spectrometry, the product structure is as follows:
- the synthesis method of this embodiment differs from Example 2 only in that the format reagent used in the step (2) is butyl magnesium bromide, and the molar ratio thereof to 5-pentafluorosulfide-2-hydroxybenzaldehyde is 3:1, except that the preparation methods and conditions are the same as in Example 2, and the NMR is characterized by nuclear magnetic resonance and mass spectrometry to determine 6-pentafluoride sulfur.
- the structure of -8-pentyl-2-trifluoromethyl-2H-benzopyran-3-carboxylic acid is as follows:
- the synthesis method of this embodiment differs from Example 2 only in that the format reagent used in the step (2) is phenyl magnesium bromide, and the molar ratio thereof to 5-pentafluorosulfide-2-hydroxybenzaldehyde is 2:1, except that the preparation methods and conditions were the same as in Example 2, and characterized by nuclear magnetic resonance spectroscopy and mass spectrometry to determine 6-pentafluorosulfide-8-benzyl-2-trifluoromethyl-2H-
- the structure of benzopyran-3-carboxylic acid is as follows:
- the synthesis method of this embodiment differs from Embodiment 2 only in the format used in the step (2).
- the reagent is 3-methyl-2-pyridylmagnesium bromide, and the molar ratio thereof to 5-pentafluorosulfuric acid 2-hydroxybenzaldehyde is 2:1, and the preparation method and conditions are the same as the examples. 2 identical, characterized by mass spectrometry, to determine the structure of 6-pentafluoride-8-benzyl-2-trifluoromethyl-2H-benzopyran-3-carboxylic acid as follows:
- the synthetic route is as follows:
- the synthesis method of this example differs from Example 1 only in that a chiral catalyst 2-[diphenyl[(trimethylsilyl)oxy]methyl]-pyrrole is used in the reaction of the step (5).
- the molar ratio of the alkane to the 5-pentafluorosulfide-2-hydroxy-3-methylbenzaldehyde is 4:1, except that the preparation method and conditions are the same as in the first embodiment, and the nuclear magnetic resonance spectrum and Characterization by mass spectrometry, the structure of (S)-6-pentafluoride-8-methyl-2-trifluoromethyl-2H-benzopyran-3-carboxylic acid was determined as follows:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (12)
- 根据权利要求1所述的4-五氟化硫苯酚类化合物,其特征在于,R1选自C1~C8烷基、C6~C11烷基芳基或C4~C6杂环基中的任意一种。
- 根据权利要求1所述的4-五氟化硫苯酚类化合物的制备方法,其特征在于,所述制备方法为:化合物I与硼氢化钠或格式试剂反应得到化合物II,反应式如下:其中,R1选自氢、C1~C10烷基、C6~C15烷基芳基或C3~C8杂环基中的任意一种;优选地,以4-五氟化硫苯酚为原料制备得到所述化合物I,其制备方法为:4-五氟化硫苯酚与六亚甲基四胺在酸液中反应得到化合物I,反应式如下:优选地,所述酸液为多聚磷酸、冰醋酸或三氟乙酸中的任意一种或至少两种的组合,优选三氟乙酸;优选地,所述4-五氟化硫苯酚与六亚甲基四胺的摩尔比为1∶1.2~1∶2,优选1∶1.5;优选地,相对于1g 4-五氟化硫苯酚,所述酸液的用量为5~15mL;优选地,所述4-五氟化硫苯酚与六亚甲基四胺在酸液中反应的温度为70~90℃,优选80℃;优选地,所述4-五氟化硫苯酚与六亚甲基四胺在酸液中反应的时间为5~24小时,优选12~18小时;优选地,所述格式试剂的分子式为R3MgX,R3为C1~C10烷基、C6~C15烷基芳基或C3~C8杂环基中的任意一种,X为卤素;优选地,所述格式试剂为甲基格式试剂或乙基格式试剂,进一步优选为甲基溴化镁或乙基溴化镁;优选地,所述化合物I与硼氢化钠或格式试剂的摩尔比为1∶2~4,优选为1∶4;优选地,所述化合物I与硼氢化钠或格式试剂反应的溶剂为C1~C4醇,优选乙醇;优选地,相对于1g化合物I,所述溶剂的用量为10~20mL;优选地,所述化合物I与硼氢化钠或格式试剂的反应在回流条件下进行;优选地,所述化合物I与硼氢化钠或格式试剂反应的时间为1~5小时。
- 一种五氟化硫取代苯并吡喃类化合物的制备方法,其特征在于,所述方法包括以下步骤:(1)化合物II与氯甲酸酯反应,而后与硼氢化钠反应得到化合物III(a),反应式如下:(2)化合物III(a)与六亚甲基四胺在酸液中反应得到化合物IV,反应式如下:(3)化合物IV与4,4,4-三氟巴豆酸乙酯、弱碱在溶剂中反应得到化合物V,反应式如下:(4)化合物V用碱水解,而后用酸中和,得到产物VI,反应式如下:其中,R1和R独立地选自氢、C1~C10烷基、C6~C15烷基芳基或C3~C8杂环基中的任意一种;优选地,R1和R选自C1~C8烷基、C6~C11烷基芳基或C4~C6杂环基中的任意一种;
- 根据权利要求7所述的制备方法,其特征在于,步骤(1)所述氯甲酸酯为氯甲酸甲酯、氯甲酸乙酯、氯甲酸丙酯或氯甲酸丁酯中的任意一种或至少两种的组合,优选氯甲酸乙酯;优选地,步骤(1)所述化合物II与氯甲酸酯的摩尔比为1∶2~3;优选地,步骤(1)所述化合物II与硼氢化钠的摩尔比为1∶8~10;优选地,步骤(1)所述化合物II与氯甲酸酯的反应所用溶剂为二氯甲烷和/或三氯甲烷;优选地,步骤(1)所述化合物II与氯甲酸酯的反应在弱碱性物质存在下进行;优选地,所述弱碱性物质为三乙胺、碳酸钾、碳酸铯或氟化铯中的任意一种或至少两种的组合,优选三乙胺;优选地,所述化合物II与弱碱性物质摩尔比为1∶2~10,优选1∶6;优选地,步骤(1)所述化合物II与氯甲酸酯反应的温度为0~30℃;优选地,步骤(1)所述化合物II与氯甲酸酯反应的时间为1-5小时;优选地,步骤(1)所述化合物II与硼氢化钠反应的温度为0-30℃;优选地,步骤(1)所述化合物II与硼氢化钠反应的时间为1-5小时;优选地,步骤(2)所述酸液为三氟乙酸、多聚磷酸或冰醋酸中的任意一种或至少两种的组合,优选三氟乙酸;优选地,步骤(2)所述化合物III(a)与六亚甲基四胺的摩尔比为1∶1.2~2,优选1∶1.7;优选地,相对于1g化合物III(a),步骤(2)所述酸液的用量为10~30mL;优选地,步骤(2)所述反应的温度为60~100℃,优选80℃;优选地,步骤(2)所述反应的时间为8-48小时,优选12-18小时;优选地,步骤(3)所述化合物IV与4,4,4-三氟巴豆酸乙酯的摩尔比为1∶1.2~10,优选1∶5;优选地,步骤(3)所述弱碱为三乙胺、碳酸钾、碳酸铯或氟化铯中的任意一种或至少两种的组合,优选三乙胺;优选地,相对于1g化合物IV,步骤(3)所述弱碱的用量为10-20mL;优选地,步骤(3)所述溶剂为三乙胺、四氢呋喃、N,N-二甲基甲酰胺或二甲基亚砜中的任意一种或至少两种的组合;优选地,步骤(3)所述反应的温度为80-120℃;优选地,步骤(3)所述反应的时间为10-72小时,优选12-20小时;优选地,步骤(4)所述碱为氢氧化钾、氢氧化钠或氢氧化锂中的任意一种或至少两种的组合;优选地,步骤(4)所述化合物V与碱的摩尔比为1∶10~20;优选地,步骤(4)所述用碱水解的温度为20-30℃;优选地,步骤(4)所述用碱水解的时间为1-5小时;优选地,步骤(4)所述酸为盐酸和/或硫酸。
- 根据权利要求7或8所述的制备方法,其特征在于,所述制备方法包括以下步骤:(1)4-五氟化硫苯酚与六亚甲基四胺在三氟乙酸中反应得到化合物I,反应式如下:(2)化合物I与硼氢化钠或格式试剂反应得到化合物II,反应式如下:(3)化合物II与氯甲酸乙酯在三乙胺存在下反应,而后与硼氢化钠反应得到化合物III(a),反应式如下:(4)化合物III(a)与六亚甲基四胺在三氟乙酸中反应得到化合物IV,反应式如下:(5)化合物IV与4,4,4-三氟巴豆酸乙酯、三乙胺在溶剂中反应得到化合物V,反应式如下:(6)化合物V用碱水解,而后用酸中和,得到产物VI,反应式如下:其中,R1和R独立地选自氢、C1~C10烷基、C6~C15烷基芳基或C3~C8杂环基中的任意一种;优选地,产物VI为消旋体化合物,为了得到其手性化合物,在化合物IV与4,4,4-三氟巴豆酸乙酯的反应中加入手性催化剂;优选地,所述手性催化剂为二苯基脯氨硅酯类或二萘基脯氨硅酯类化合物;进一步优选地,所述手性催化剂为(2S)-2-[二苯基[(三甲基硅酯)氧基]甲基]-吡咯烷或(2R)-2-[二苯基[(三甲基硅酯)氧基]甲基]-吡咯烷;优选地,所述手性催化剂与化合物IV的摩尔比为1∶4-6,优选1∶5。
- 一种五氟化硫取代苯并吡喃类化合物的制备方法,其特征在于,所述制备方法包括以下步骤:A、化合物III(b)与氧化剂反应得到化合物IV(b),反应式如下:B、化合物IV(b)与4,4,4-三氟巴豆酸乙酯、弱碱在溶剂中反应得到化合物V(b),反应式如下:C、化合物V(b)用碱水解,而后用酸中和,得到产物VI(b),反应式如下:其中,R1选自氢、C1~C10烷基、C6~C15烷基芳基或C3~C8杂环基中的任意一种,R2为卤素;优选地,R1选自C1~C8烷基、C6~C11烷基芳基或C4~C6杂环基中的任意一种;
- 根据权利要求10所述的制备方法,其特征在于,步骤A所述氧化剂为氯铬酸吡啶盐和/或二氧化锰;优选地,步骤A所述化合物III(b)与氧化剂的摩尔比为1∶2~20;优选地,步骤A所述反应的温度为10-30℃;优选地,步骤A所述反应的时间为5-24小时;优选地,步骤B所述化合物IV(b)与4,4,4-三氟巴豆酸乙酯的摩尔比为1∶1.2~10,优选1∶5;优选地,步骤B所述弱碱为三乙胺、碳酸钾、碳酸铯或氟化铯中的任意一种或至少两种的组合,优选三乙胺;优选地,相对于1g化合物IV(b),步骤B所述弱碱的用量为10-20mL;优选地,步骤B所述溶剂为三乙胺、四氢呋喃、N,N-二甲基甲酰胺或二甲基亚砜中的任意一种或至少两种的组合;优选地,步骤B所述反应的温度为80-120℃;优选地,步骤B所述反应的时间为10-72小时,优选12-20小时;优选地,步骤C所述碱为氢氧化钾、氢氧化钠或氢氧化锂中的任意一种或至少两种的组合;优选地,步骤C所述化合物V(b)与碱的摩尔比为1∶10~20;优选地,步骤C所述用碱水解的温度为20-30℃;优选地,步骤C所述用碱水解的时间为1-5小时;优选地,步骤C所述酸为盐酸和/或硫酸。
- 根据权利要求10或11所述的制备方法,其特征在于,所述方法包括以下步骤:(1)4-五氟化硫苯酚与六亚甲基四胺在酸液中反应得到化合物I,反应式如下:(2)化合物I与硼氢化钠或格式试剂反应得到化合物II,反应式如下:(3)化合物II与卤化试剂反应得到化合物III(b),反应式如下:(4)化合物III(b)与氧化剂反应得到化合物IV(b),反应式如下:(5)化合物IV(b)与4,4,4-三氟巴豆酸乙酯、弱碱在溶剂中反应得到化合物V,反应式如下:(6)化合物V(b)用碱水解,而后用酸中和,得到产物VI(b),反应式如下:其中,R1选自氢、C1~C10烷基、C6~C15烷基芳基或C3~C8杂环基中的任意一种,R2为卤素。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018547883A JP6912143B2 (ja) | 2016-03-09 | 2016-06-22 | 4−ペンタフルオロチオフェノール類化合物と調製方法及びペンタフルオロサルファー置換ベンゾピラン化合物の調製方法 |
US16/083,485 US10414744B2 (en) | 2016-03-09 | 2016-06-22 | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound |
EP16893185.5A EP3428154A1 (en) | 2016-03-09 | 2016-06-22 | 4-sulfur pentafluoride phenol compound and preparation method therefor, and preparation method for sulfur pentafluoride substituted benzopyran compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610133812.2A CN105585547A (zh) | 2016-03-09 | 2016-03-09 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
CN201610133812.2 | 2016-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017152539A1 true WO2017152539A1 (zh) | 2017-09-14 |
Family
ID=55925488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/086772 WO2017152539A1 (zh) | 2016-03-09 | 2016-06-22 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10414744B2 (zh) |
EP (1) | EP3428154A1 (zh) |
JP (1) | JP6912143B2 (zh) |
CN (1) | CN105585547A (zh) |
WO (1) | WO2017152539A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105585547A (zh) * | 2016-03-09 | 2016-05-18 | 中国科学院广州生物医药与健康研究院 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
CN109678701B (zh) * | 2019-01-22 | 2021-08-20 | 安徽德信佳生物医药有限公司 | 一种维兰特罗中间体的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150197500A1 (en) * | 2014-01-14 | 2015-07-16 | Euclises Pharmaceuticals, Inc. | No-releasing guanidine-chromene conjugates |
WO2015109011A1 (en) * | 2014-01-14 | 2015-07-23 | Euclises Pharmaceuticals, Inc. | No-releasing nitrooxy-chromene conjugates |
CN105585547A (zh) * | 2016-03-09 | 2016-05-18 | 中国科学院广州生物医药与健康研究院 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030957B2 (en) | 2009-03-25 | 2011-10-04 | Aehr Test Systems | System for testing an integrated circuit of a device and its method of use |
CN102439005B (zh) * | 2009-05-07 | 2015-07-22 | 杨森制药公司 | 作为γ-分泌酶调节剂的取代的吲唑和氮杂-吲唑衍生物 |
WO2015109014A1 (en) * | 2014-01-14 | 2015-07-23 | Euclises Pharmaceuticals, Inc. | No-releasing nonoate(oxygen-bound)chromene conjugates |
CN104860914B (zh) * | 2014-02-26 | 2018-09-14 | 中国科学院广州生物医药与健康研究院 | 五氟化硫取代苯并吡喃类化合物及其应用 |
-
2016
- 2016-03-09 CN CN201610133812.2A patent/CN105585547A/zh active Pending
- 2016-06-22 WO PCT/CN2016/086772 patent/WO2017152539A1/zh active Application Filing
- 2016-06-22 EP EP16893185.5A patent/EP3428154A1/en not_active Withdrawn
- 2016-06-22 US US16/083,485 patent/US10414744B2/en active Active
- 2016-06-22 JP JP2018547883A patent/JP6912143B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150197500A1 (en) * | 2014-01-14 | 2015-07-16 | Euclises Pharmaceuticals, Inc. | No-releasing guanidine-chromene conjugates |
WO2015109011A1 (en) * | 2014-01-14 | 2015-07-23 | Euclises Pharmaceuticals, Inc. | No-releasing nitrooxy-chromene conjugates |
CN105585547A (zh) * | 2016-03-09 | 2016-05-18 | 中国科学院广州生物医药与健康研究院 | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US10414744B2 (en) | 2019-09-17 |
EP3428154A1 (en) | 2019-01-16 |
JP6912143B2 (ja) | 2021-07-28 |
JP2019509293A (ja) | 2019-04-04 |
US20190084957A1 (en) | 2019-03-21 |
CN105585547A (zh) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5048017B2 (ja) | 置換フェニルアルカン酸誘導体及びその用途 | |
KR910007970B1 (ko) | 4h-1-벤조피란-4-온 유도체 또는 이의 염, 이의 제조방법 및 활성 성분으로서 이를 함유하는 약제학적 조성물 | |
CZ2004220A3 (cs) | Název neuveden | |
US10040771B2 (en) | Method for preparing prostacyclin receptor agonist 4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]-1-butanol | |
CN111201212A (zh) | 一种非罗考昔及其中间体的合成方法 | |
WO2021254469A1 (zh) | 一种罗沙司他及其中间体的合成方法和其中间体 | |
WO2022121853A1 (zh) | 2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸的制备方法 | |
WO2017152539A1 (zh) | 一种4-五氟化硫苯酚类化合物及制备方法以及五氟化硫取代苯并吡喃类化合物的制备方法 | |
RU2236405C2 (ru) | Полициклические тиазолидин-2-илиденовые амины, содержащие их лекарственные средства и способ получения лекарственного средства | |
WO2008044729A1 (en) | Carboxylic acid derivative | |
CN110862372B (zh) | 氯吡格雷中间体(s)-2-(2-噻吩乙胺基)-(2-氯苯基)-乙酸甲酯的合成 | |
WO2019047654A1 (zh) | 一种取代苯乙酸衍生物的制备方法 | |
WO2022134261A1 (zh) | 胆绿素类化合物及其制备方法和用途 | |
TWI725710B (zh) | 3-溴-5-(2-乙基咪唑並[1,2-a]吡啶-3-羰基)-2-羥基苯甲腈的合成 | |
JPH10226683A (ja) | 2−(10,11−ジヒドロ−10−オキソジベンゾ[b,f]チエピン−2−イル)プロピオン酸の製造方法、及びその中間体化合物 | |
CN104230782A (zh) | 一种赛洛多辛的合成方法 | |
WO2020125581A1 (zh) | 一种类酰胺类衍生物及其中间体的制备方法 | |
WO2011082623A1 (zh) | 一种非布索坦的制备方法 | |
JPH03261778A (ja) | 新規ベンゾフラン誘導体、尿酸排泄剤及びその製法 | |
CN115160285B (zh) | 硫代酰胺类aldh2激动剂、制备方法及应用 | |
CN107935909A (zh) | 一种尼达尼布(nintedanib)及其中间体的合成方法 | |
WO2009012679A1 (fr) | Composés de 2,2,3a,4-tétrahydrothiochromène[4,3-c]pyrazole, leur procédé de préparation et utilisation | |
CN111848552A (zh) | 一种3-(取代苯基)氧杂环丁烷-3-羧酸及其中间体的制备方法及应用 | |
WO2022134260A1 (zh) | 胆绿素或其衍生物的制备方法 | |
CN106749201A (zh) | 一种沃拉帕沙及其中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018547883 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016893185 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016893185 Country of ref document: EP Effective date: 20181009 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16893185 Country of ref document: EP Kind code of ref document: A1 |